DUBLIN – Eli Lilly and Co. is paying Keybioscience AG $55 million up front and is also on the hook for potential milestone payments arising from an alliance focused on a new drug class, dubbed dual amylin calcitonin receptor agonists (Darcas), in development for diabetes and other metabolic diseases.